Agenda will run 8.20am - 6.00pm CET

8:00 am Virtual Coffee Networking Morning

8:20 am Chair’s Opening Remarks

Precision Medicine Application Across an Evolving European Landscape: Exciting Advancements & Current Socio-Political Environment

8:30 am The Translational Perspective: Early Biomarker Decisions Today to Influence Precision Medicine Successes of Tomorrow

Synopsis

  • Starting with the end in mind: Early biomarker decisions for down the line precision medicine success and optimise outcomes for patients
  • Working with your stakeholders to devise a robust biomarker programme
  • Bridging the preclinical and clinical gap, and translating clinically validated predictive biomarkers with improved treatment outcomes

9:00 am Moving Diagnostic Providers to the Forefront of Precision Medicine

Synopsis

• Role of the Diagnostic Laboratory in CDx commercialization – Key Considerations and Day 1 Readiness
• CDx Case Studies including PIK3CA – discussing the full spectrum of CDx development from bench to bedside
• Lab Challenges: Perspectives on lessons learned and future paradigms for CDx/Dx development

9:30 am Pharma & Central Lab – An Innovative Way of Working for Deployment of a Successful Companion Diagnostic Development Program

  • Alan Wookey Global Head, Companion Diagnostics, Q2 Solutions
  • Kristina McGuire Senior Director and Head of CDx & Lab Operations, Precision Medicine, Regeneron

Synopsis

• Alignment on objectives to deliver CDx data from a global study across 4 locations
• Pioneering an innovative Operational Model to enhance success
• Challenges and mitigation

10:00 am Panel Discussion: Current Socio-Political & the Changing Healthcare Landscape Influences on Precision Medicine Delivery in the EU

  • Michael Schubert Editor , The Pathologist Journal
  • Laura Perez-Cano Head of Discovery and Data Science , Stalicla
  • Lynn Durham Chief Executive Officer, Stalicla
  • Ejner Moltzen Advisor, Innovation Fund Denmark, Chair, International Consortium for Personalized Medicine
  • Seamus Kearney Chief Executive Officer and Principal Consultant , ARC Regulatory Ltd.

Synopsis

  • Implications of Covid-19 on the delivery of precision medicine
  • Following Brexit: How are impacts being felt across the industry and potential disruptions to targeted therapy development
  • Precision medicine in the EU: A leading precision medicine market but where can we improve? Highlighting challenges connecting a diverse landscape to deliver better treatment outcomes
  • With IVDR regulations coming into effect in just over a year in the EU – Where are we now? What bottlenecks are foreseen for precision medicine implementation come May 2022?

10:45 am Speed Networking & Coffee Networking Break

12:45 pm Networking Lunch

Synopsis

Whilst enjoying a bite to eat, you can take part in:

  • 121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the biomarker-driven drug development space
  • Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward

3:15 pm Afternoon Speed Networking Break

3:45 pm Panel Discussion: Women & Diversity in Precision Medicine

  • Maggie Cheang Team Leader of Integrative Genomic Analysis in Clinical Trials, Institute of Cancer Research
  • Madhushree Ghosh Vice President, Strategic Alliances & Projects BioPharma Services, NeoGenomics Laboratories
  • Karen Lauxmann European Sales Lead Contract Manufacturing, Pfizer CentreOne
  • Jennifer O’Lear Director, Chief Diversity Officer, Head of Engagement & Inclusion , Merck Group
  • Elena Hernandez Cebrecos Director Global Talent & Inclusion Business Partner, Global Drug Development , Novartis
  • Rahul Sharma Vice President, Global People & Organization Head, Technical R&D, Novartis

Synopsis

This panel discussion is designed to bring value to all leaders in healthcare looking to unlock the potential of their team, career and business. Through tapping into multiple diverse perspectives and experiences we can accelerate innovation and drive progress in the provision of personalised care.

Data & Advanced Technology in Rare Disease: Generating Insights for Faster & More Focussed Patient Stratification

Moderator: Guillaume Desachy, Principal Biostatistician, AstraZeneca

4:45 pm Harnessing Transcriptional Profiling for Immune-Based Cancer Patient Stratification

  • Xavier Solé Acha Head of Unit of Bioinformatics for Precision Oncology, Catalan Institute of Oncology

Synopsis

  • Deconvolution of bulk gene expression tumour data allows for a comprehensive quantification of a complete set of immune cell fractions within the tumor context
  • The quantification of immune cell fractions can contribute to identify those immune cell types which may have a role in patient survival, and therefore contribute to a more precise stratification of patients based on their predicted prognosis
  • The use of functional signatures of drug response can also contribute to identify potential therapeutic strategies specific for each one of the identified immune-based groups

5:15 pm NY-ESO-1 TCR T-cell Therapy in Synovial Sarcoma

  • Ellie Corigliano Global Director Medical Affairs, Oncology, Thoracic & Pan Tumor Biomarkers & Diagnostics, Oncology Global Medical Affairs, Merck & Co.

Synopsis

• Letetresgene autoleucel (lete-cel; GSK3377794) is a T-cell receptor (TCR) T-cell therapy specific to the NY-ESO-1 peptide-displaying antigen, a highly immunogenic cancer/testis antigen expressed in synovial sarcoma, that promotes an anticancer immune response.
• A Phase I study in patients with previously-treated advanced synovial sarcoma whose tumors express NY-ESO-1 protein indicated that lete-cel infusion was associated with response rates.
• Early development of NY-ESO-1 immunohistochemistry detection suggests a companion diagnostic path forward clinical development.

5:45 pm Chair’s Closing Remarks

6:00 pm End of Day 1

Synopsis

Just because we can’t meet in person, doesn’t mean you can’t have those face to face interactions with your precision oncology peers. Take part in group networking or use the private chat functions to meet fresh and familiar faces and reflect on Day One of the meeting.
We look forward to welcoming you back for Day Two!